
Proteomimetic Peptide Platform
Proteomimetic peptidic constructs are non-natural self-organizing biomimicking systems. They exhibit similar properties to those of proteins, e.g. they have a tendency to fold into specific periodic compact structures with given biomedical function.
Proteomimetic peptidic constructs have biological applications where the tailored 3D structure is crucial.
They are a novel class of drug scaffolds with tailored molecular shape and surface.
We developed a novel and highly efficient technology (a continuous-flow meso-scale reactor) to synthesize such proteomimetic peptides and their derivatives.
The complete characterization of the peptidic construct is routinely performed in our state of the art facilities equipped with LD/CD spectrophotometer, NMR spectrometers, custom-made SAXS, WAXS instruments, FF-TEM, SFG spectroscopy, spectrofluorimeter and HPLC.
Proteomimetic peptidic drugs
Proteomimetic peptidic drug candidates can replace the biological role of the non-functional proteins:
-
Novel, functionally designed peptides with a distinct biological activity such as enzyme inhibition, cell membrane penetration, antiviral or antifungal effect.
-
Conjugation with small molecule for desired pharmacological effect, but different mode of action.
The proteomimetic peptide conjugate possesses higher biological activity than those of its building blocks.


Pipeline
EPIPHARMA develops a Peptide IBD In vitro Diagnostic Product and first-in class Proteomimetic Peptide Drugs for patients with major unmet clinical needs.
IBD In vitro Diagnostics
EPI-051
Development Phase
Phase II
Indication
Artificial saliva (Xerostomia)
EPI-031
Development Phase
Pre-clinical
Indication
IN VITRO DIAGNOSTICS & MEDICAL DEVICES
Development Phase
Candidate | Indication | Discovery | Pre-clinical | Phase I | Phase II | Phase III |
---|---|---|---|---|---|---|
EPI-051 | IBD In vitro Diagnostics | |||||
EPI-031 | Artificial saliva (Xerostomia) |
Antifungal NCE
EPI-024
Development Phase
Pre-clinical
Indication
Anticoagulant NCE
EPI-061
Development Phase
Pre-clinical
Indication
Mitochondrial Ca2+ overload treatment
EPI-041
Development Phase
Discovery
Indication
Cystic fibrosis
EPI-025
Development Phase
Discovery
Indication
DRUGS
Development Phase
Candidate | Indication | Discovery | Pre-clinical | Phase I | Phase II | Phase III |
---|---|---|---|---|---|---|
EPI-024 | Antifungal NCE | |||||
EPI-061 | Anticoagulant NCE | |||||
EPI-041 | Mitochondrial Ca2+ overload treatment | |||||
EPI-025 | Cystic fibrosis |